243
Participants
Start Date
August 4, 2010
Primary Completion Date
May 31, 2011
Study Completion Date
May 31, 2011
PF-00489791
Subjects with Secondary Raynaud's Phenomenon will receive PF-00489791 4 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
PF-00489791
Subjects with Secondary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 4 mg once a day for the second 4 week cross over period
PF-00489791
Subjects with Secondary Raynaud's Phenomenon will receive PF-00489791 20 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
PF-00489791
Subjects with Secondary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 20 mg once a day for the second 4 week cross over period
PF-00489791
Subjects with Primary Raynaud's Phenomenon will receive PF-00489791 4 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
PF-00489791
Subjects with Primary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 4 mg once a day for the second 4 week cross over period
PF-00489791
Subjects with Primary Raynaud's Phenomenon will receive PF-00489791 20 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
PF-00489791
Subjects with Primary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 20 mg once a day for the second 4 week cross over period
Semmelweis Egyetem, Ersebeszeti Klinika, Budapest
Bacs-Kiskun Megyei Onkormanyzat Korhaza Szegedi Tudomanyegyetem AOK Oktato Korhaza, Kecskemét
Vas Megyei Markusovszky Korhaz Nonprofit Zrt, Angiologiai Szakambulancia, Szombathely
The Center for Rheumatology, Albany
Regional Rheumatology Associates, Binghamton
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City
AAIR Research Center, Rochester
Hospital Clinico Universitario Santiago de Compostela, Santiago de Compostela
Altoona Center for Clinical Research, Duncansville
East Penn Rheumatology Associates, PC, Bethlehem
Rheumatic Disease Associates, Ltd., Willow Grove
Georgetown University Hospital, Washington D.C.
The Center for Rheumatology and Bone Research, Wheaton
Johns Hopkins University - Division of Rheumatology, Baltimore
Dermatologisches Ambulatorium Hamburg-Alstertal, Hamburg
Hospital Universitario 12 de Octubre, Madrid
Arthritis and Rheumatology of Georgia, Atlanta
Unidad de Investigacion en Enfermedades Cronico Degenerativas, Guadalajara
Diagnostic Rheumatology and Research, PC, Indianapolis
Memorial Health System, Inc. dba Memorial Medical Group Clinical Research Institute, South Bend
University of Michigan, Ann Arbor
University of Michigan Health System, Ann Arbor
West Michigan Rheumatology, PLLC, Grand Rapids
Rockford Orthopedic Associates, Rockford
Physician Research Collaboration, LLC, Lincoln
Metroplex Clinical Research Center, Dallas
Hospital Angeles. Centro Medico del Potosi, San Luis Potosí City
Stanford Hospital and Outpatient Center, Redwood City
Rainier Clinical Research Center, Inc., Renton
University of Connecticut Health Center, Farmington
Clinical Pharmacology Study Group, Worcester
UMDNJ - Robert Wood Johnson Medical Center Clinical Research Center, New Brunswick
Arthritis Centre Health Sciences Centre, Winnipeg
St. Joseph's Health Centre, London
Rheumatology Research Associates, Ottawa
Sir Mortimer B. Davis, Jewish General Hospital, Montreal
Centro Integral de Reumatologia e Inmunologia CIREI, Bogota
Fundacion Instituto de Reumatologia Fernando Chalem, Bogota
Idearg Sas, Bogotá
Servimed E.U, Bucaramanga
Medicity S.A.S, Bucaramanga
REVMATOLOGIE s.r.o.,, Brno
Fakultni nemocnice Hradec Kralove, Hradec Králové
Revmatologicky ustav, Prague
Slaskie Centrum Osteoporozy, Katowice
Prywatna Praktyka Lekarska Dr Med. Pawel Hrycaj, Poznan
Prywatna Praktyka Lekarska Prof. UM Dr hab. med. Pawel Hrycaj, Poznan
Katedra i Klinika Dermatologii, Wenerologii i Alergologii Akademii Medycznej we Wroclawiu, Wroclaw
Seoul National University Hospital, Rheumatology, Internal Medicine, Seoul
Yonsei University College of Medicine, Severance Hospital, Rheumatology, Internal Medicine, Seoul
The Catholic University of Korea, Seoul St. Mary's Hospital/ Rheumatology, Internal Medicine, Seoul
Hospital Del Mar, Barcelona
CTC, Centrum för klinisk provning, Sahlgrenska Universitetssjukhuset, Gothenburg
Reumatologkliniken Skanes Universitetssjukhus Lund, Lund
Karolinska Universitetssjukhuset Solna, Reumatologiska kliniken, Stockholm
Lead Sponsor
Pfizer
INDUSTRY